Halozyme Therapeutics, Inc.

US$103.63As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:HALOHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 28.15%
Div yield —
ROE 216.38%
Biotechnology
Beta (5Y) 0.90
PE TTM 26.10
TSR TTM 58.97%
Mkt cap US$11.81B
ROIC 29.76%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$111
7.52%
11.23%
Hold 4|7|2|1|0
4Q25
1Q26
2Q26
3Q26
Earnings per share$
1.91
2.09
2.24
2.36
20.45%
32.48%
37.71%
37.91%
Revenue$M
807.9
788.5
779.8
803.9
(0.62%)
(3.53%)
(2.76%)
0.07%
Peers (US$11.81B)
Cap (US$)
PE
11.43B
66.21x
Capital
TTM
5Y
10Y
Leveragex
0.267
0.123
0.148
EBIT/Intx
4.028
0.038
0.044
Own earn%
177.30
(4.23)
(12.26)
Sh yield%
31.64
21.85
18.64
Owners
Insiders/Inst%
6.47
21.11
Short interest%
2.52
SBC / revenue%
2.36
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
22
Op margin range%
19–28
$1 testx
0.0
Incr. ROIC%
1